News
-
-
-
-
PRESS RELEASE
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Heidelberg Pharma AG and Huadong Medicine receive NMPA approval for Phase Ib/II clinical trial of HDP-101 combination therapy in China. Evaluation of BCMA-targeting ADC in patients with multiple myeloma -
-
-
-
REGULATED PRESS RELEASE
Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Altarea and Praemia group settle dispute with comprehensive agreement, including settlement payment of €10 million. Praemia strengthens equity base with €60 million subscription by Altarea -
PRESS RELEASE
MACOMPTA.FR accelerates its AI strategy with the launch of Emma and prepares the deployment of a new generation of intelligent agents
MACOMPTA.FR announces launch of AI agent Emma to enhance user experience and prepares for deployment of new intelligent agents in 2026-2027 to automate accounting processes and provide insights -
PRESS RELEASE
LIGHTON: Information concerning the total number of voting rights and shares in the share capital as of 31 July 2026.
LIGHTON provides information on the total number of voting rights and shares in the share capital as of 31 July 2026, including new shares issued for bond financing. LightOn is a European AI company listed on Euronext Growth